We are live on ! Find out more
NUVB icon

Nuvation Bio

148 hedge funds and large institutions have $447M invested in Nuvation Bio in 2024 Q2 according to their latest regulatory filings, with 39 funds opening new positions, 45 increasing their positions, 39 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

214% more capital inflows, than outflows

Capital inflows: $79.4M | Capital outflows: $25.3M

144% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 16

50% more call options, than puts

Call options by funds: $30K | Put options by funds: $20K

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

19% more funds holding

Funds holding: 124 → 148 (+24)

15% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 39

0.17% more ownership

Funds ownership: 61.75% → 61.92% (+0.17%)

Holders
148
Holders Change
+24
Holders Change %
+19.35%
% of All Funds
2.13%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.06%
New
39
Increased
45
Reduced
39
Closed
16
Calls
$30​K
Puts
$20​K
Net Calls
+$10​K
Net Calls Change
-⁠$205​K

NUVB Hedge Fund Activity: Q2 2024 in Review

148 of the 6,945 institutional investors tracked by Wall St. Rank reported a position in Nuvation Bio (NUVB) for Q2 2024, worth a combined $447M — down 8.8% from $490M a quarter earlier.

Buyers outnumbered sellers: 39 funds opened new NUVB positions and 16 closed out — a net gain of 23 holders — while 45 added to existing stakes and 39 trimmed.

The largest buyer was Decheng Capital, opening a new position worth an estimated $21.2M. The largest seller was T. Rowe Price Associates, cutting an estimated $3.46M.

  • 148 institutional investors held Nuvation Bio (NUVB) as of Q2 2024, up from 124 in Q1 2024.
  • Funds reported $447M of Nuvation Bio stock for Q2 2024, down 8.8% quarter-over-quarter.
  • 39 funds opened new Nuvation Bio positions in Q2 2024 and 16 closed out, a net change of +23 holders.
  • The largest Nuvation Bio buyer in Q2 2024 was Decheng Capital, an estimated $21.2M added.
  • The largest Nuvation Bio seller in Q2 2024 was T. Rowe Price Associates, an estimated $3.46M sold.

Based on aggregated 13F filings for Q2 2024.